R

Reata Pharmaceuticals Inc
F:2R3

Watchlist Manager
Reata Pharmaceuticals Inc
F:2R3
Watchlist
Price: 161 EUR Market Closed
Market Cap: 6B EUR

Net Margin
Reata Pharmaceuticals Inc

-373.2%
Current
-5 711%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-373.2%
=
Net Income
-87.6m
/
Revenue
23.5m

Net Margin Across Competitors

No Stocks Found

Reata Pharmaceuticals Inc
Glance View

Reata Pharmaceuticals Inc., based in Plano, Texas, has crafted its narrative around the relentless pursuit of innovative therapies targeting serious and life-threatening diseases. The company's story began with a profound commitment to addressing rare genetic diseases affecting the central nervous system—conditions often overlooked by larger pharmaceutical enterprises due to their complexity and limited patient populations. Reata's strategy revolves around leveraging its expertise in molecular biology to develop unique therapeutic solutions that modulate biochemical pathways. Its lead compounds, such as Omaveloxolone, are designed to combat oxidative stress—an underlying pathophysiological factor in many neurological disorders. The company’s business model finds equilibrium between high-stakes innovation and strategic partnerships. By targeting rare diseases with niche but under-penetrated markets, Reata can potentially command premium pricing for its treatments, often under the auspices of orphan drug status which provides regulatory and market exclusivity advantages. Beyond its own pipeline advancements, Reata also extends its financial reach through strategic alliances with major industry players, enhancing its capital influx and accelerating drug development. The complex tapestry of cutting-edge science, strategic foresight, and the ability to navigate regulatory landscapes paints Reata Pharmaceuticals as not only a beacon of hope for patients but also a dynamic player in the biopharmaceutical sector.

2R3 Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-373.2%
=
Net Income
-87.6m
/
Revenue
23.5m
What is the Net Margin of Reata Pharmaceuticals Inc?

Based on Reata Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -373.2%.

Back to Top